Biotech firm Abivax has re-engaged investment bank Centerview to facilitate discussions regarding a potential takeover by a Big Pharma company. The development highlights the company's strategic intent to explore acquisition opportunities as it seeks to align with larger pharmaceutical entities.

Strategic Partnership

Abivax's decision to bring back Centerview underscores its focus on securing a deal with a major pharmaceutical player. The investment bank's involvement suggests that serious negotiations are underway, potentially leading to a significant merger or acquisition in the biotech space.

Market Implications

The re-engagement of Centerview comes amid a broader trend of consolidation in the pharmaceutical industry. Big Pharma companies have been actively seeking innovative biotech firms to bolster their pipelines, making Abivax an attractive target given its specialized focus.

Key Details

The outcome of these discussions could reshape Abivax's future trajectory and provide it with the resources needed to scale its operations and expand its market reach.

Abivax SA (NASDAQ: ABVX) has closed its previously announced upsized public offering, generating aggregate gross proceeds of approximately $920.0 million (€807.4 million). The offering consisted of 7,360,000 American Depositary Shares (ADSs), representing the full exercise of the underwriters' option to purchase an additional 960,000 ADSs. The estimated net proceeds to the company are approximately $874.1 million (€767.1 million). The company intends to use these funds to finance the potential commercialization of its lead drug candidate, obefazimod, in the United States, clinical research and development expenses related to ulcerative colitis and Crohn’s disease, and for general corporate purposes.

With the addition of the net proceeds from this offering to its existing cash and cash equivalents, Abivax believes it now has the financial resources to fund its operations into the fourth quarter of 2029. This extends the company's previous cash runway, which was projected into the second quarter of 2029 prior to the closing of this offering. As of March 31, 2026, the company reported holding cash, cash equivalents, and short-term investments of €491.6 million.

The offering was made pursuant to an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission. The Ordinary Shares issued in connection with the offering were admitted to trading on Euronext Paris on July 6, 2026. Leerink Partners acted as the stabilizing agent and reported that no stabilization activities were carried out, with the stabilization period now closed.

Leerink Partners, Morgan Stanley, Piper Sandler, and Guggenheim Securities acted as joint bookrunning managers for the offering. LifeSci Capital acted as a passive bookrunning manager, and Van Lanschot Kempen acted as lead manager.